Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims

References

• Compston A, Coles A. Multiple sclerosis. Lancet 2002;359:1221-31
   PubMed Web of Science ®Google Scholar
• McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7
   PubMed Web of Science ®Google Scholar
• Johnson KP. Therapy of relapsing forms. In: Burks JS, Johnson KP, editors. Multiple sclerosis: diagnosis, medical management, and rehabilitation. New York: Demos, 2000
   Google Scholar
• Filippini G, Brusaferri F, Sibley WA, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000;CD001331
   Google Scholar
• Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
   PubMed Web of Science ®Google Scholar
• The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94
   PubMed Web of Science ®Google Scholar
• Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498-504
   PubMed Web of Science ®Google Scholar
• Khan OA, Tselis AC, Kamholz JA, et al. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing–remitting multiple sclerosis: results after 18 months of therapy. Mult Scler 2001;7:349-53
   PubMed Web of Science ®Google Scholar
• Young PJ, Lederer C, Eder K, et al. Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis. Neurology 2006;67:804-8
   PubMedGoogle Scholar
• Binquet C, Quantin C, Le TG, et al. The prognostic value of initial relapses on the evolution of disability in patients with relapsing-remitting multiple sclerosis. Neuroepidemiology 2006;27:45-54
   PubMed Web of Science ®Google Scholar
• Gorman MP, Healy BC, Polgar-Turcsanyi M, et al. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol 2009;66:54-9
   PubMed Web of Science ®Google Scholar
• Hirst C, Ingram G, Pearson O, et al. Contribution of relapses to disability in multiple sclerosis. J Neurol 2008;255:280-87
   Google Scholar
• Tremlett H, van dM, I, Pittas F, et al. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis. Neuroepidemiology 2008;31:271-9
   PubMed Web of Science ®Google Scholar
• Correale J, Fiol M, Gilmore W. The risk of relapses in multiple sclerosis during systemic infections. Neurology 2006;67:652-59
   PubMed Web of Science ®Google Scholar
• Potagas C, Mitsonis C, Watier L, et al. Influence of anxiety and reported stressful life events on relapses in multiple sclerosis: a prospective study. Mult Scler 2008;14:1262-68
   PubMed Web of Science ®Google Scholar
• Brown RF, Tennant CC, Sharrock M, et al. Relationship between stress and relapse in multiple sclerosis: Part I. Important features. Mult Scler 2006;12:453-64
   PubMedGoogle Scholar
• Held U, Heigenhauser L, Shang C, et al. Predictors of relapse rate in MS clinical trials. Neurology 2005;65:1769-73
   PubMed Web of Science ®Google Scholar
• Tremlett H, Zhao Y, Joseph J, et al. Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatry 2008;79:1368-74
   PubMed Web of Science ®Google Scholar
• Birnbaum HG, Cremieux PY, Greenberg PE, et al. Using healthcare claims data for outcomes research and pharmacoeconomic analyses. Pharmacoeconomics 1999;16:1-8
   PubMed Web of Science ®Google Scholar
• Berger ML, Mamdani M, Atkins D, et al. Good Research Practices for Comparative Effectiveness Research: Defining, Reporting and Interpreting Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report-Part I. Value Health 2009;12:1044-52
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005;58:323-7
   PubMed Web of Science ®Google Scholar
• Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm 2002;8:469-76
   PubMedGoogle Scholar
• Health insurance portability and accountability act of 1996. Public law 104-191, 104th Congress. U S Department of Health & Human Services, 1996. Available at: http://www.cms.hhs.gov/HIPAAGenInfo/Downloads/HIPAALaw.pdf [Last accessed 12 January 2010]
   Google Scholar
• Frohman EM, Shah A, Eggenberger E, et al. Corticosteroids for multiple sclerosis: I. Application for treating exacerbations. Neurotherapeutics 2007;4:618-26
   Google Scholar
• Thrower BW. Relapse management in multiple sclerosis. Neurologist 2009;15:1-5
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112 (Pt 1):133-46
   PubMed Web of Science ®Google Scholar
• Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993;116 (Pt 1):117-34
   PubMed Web of Science ®Google Scholar
• Ollendorf DA, Castelli-Haley J, Oleen-Burkey M. Impact of co-prescribed glatiramer acetate and antihistamine therapy on the likelihood of relapse among patients with multiple sclerosis. J Neurosci Nurs 2008;40:281-90
   PubMed Web of Science ®Google Scholar
• Ford CC, Johnson KP, Lisak RP, et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler 2006;12:309-20
   PubMed Web of Science ®Google Scholar
• Goldberg LD, Edwards NC, Fincher C, et al. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm 2009;15:543-55
   PubMed Web of Science ®Google Scholar
• O'Brien JA, Ward AJ, Patrick AR, et al. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003;3:17
   PubMed Web of Science ®Google Scholar